CRISPR Therapeutics AG - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CRISPR Therapeutics AG, a company incorporated in Switzerland, on June 8, 2017. The report covers events occurring on June 7, 2017.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
The primary material change reported is the appointment of James R. Kasinger as the company's General Counsel and Secretary to the Board of Directors, effective June 7, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The document focuses solely on the executive appointment.
Key Facts for Investor Verification
- James R. Kasinger has been appointed as General Counsel and Secretary to the Board of Directors.
- The appointment was announced via a press release dated June 7, 2017 (Exhibit 99.1).
- The report was signed by Samarth Kulkarni, Ph.D., President and Chief Business Officer.